BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AiCuris Gained Bio.NRW Research Promotion


11/29/2010 12:10:20 PM

Wuppertal, Germany, November 29, 2010 / b3c newswire / – AiCuris GmbH & Co. KG has been awarded a three-year research grant together with the Universities of Bochum, Düsseldorf and Bonn as well as the company Squarix (Marl). This grant is a part of the research promotion program “Bio.NRW” by the Ministry of Innovation, Science and Research of North Rhine-Westphalia. AiCuris will obtain 833,582 Euro.

The project “Innovative Antibiotics made in NRW” is aimed to enable research and development of new antibiotics effective against life threatening multi-resistant bacteria e.g. the hospital agent MRSA (Methicillin-resistant Staphylococcus aureus). The grant is composed from funds of the “Ziel 2 – Programm NRW 2007-20013” (European fund for regional development) and from the Ministry of Innovation, Science and Research of North Rhine-Westphalia.

In its project AiCuris will evaluate the optimisation potential of underexplored natural products together with other members of the consortium. The aim is to identify a development candidate with resistance breaking properties as a new weapon to combat resistant bacteria.

Background

The steady rise of multi resistant bacteria and the absence of new effective antibiotics against life threatening, severe infections caused by them limits or even prevents a successful therapy of these agents.

The Associations for Microbiology and Medicine as well as the governments worldwide have recognised this problem and intensify their commitment to support research and development of new resistance breaking antibiotics.

About AiCuris - www.aicuris.com

AiCuris GmbH & Co KG is a privately held company located in Wuppertal, Germany. It is devoted to research and clinical development of novel, resistance-breaking drugs for the treatment of viral infections like HCMV, Herpes, Hepatitis B, HIV and Hepatitis C as well as resistant Gram-positive and Gram-negative bacterial infections in hospitals. Furthermore, the portfolio comprises two immune modulators.

Contact: AiCuris GmbH & Co. KG Sandra Wildhagen Friedrich-Ebert-Str. 475/Building 302 42117 Wuppertal Phone +49 202 317 63 0 Fax +49 202 317 63 1601 E-Mail press@aicuris.com Web www.aicuris.com



Read at BioSpace.com

AiCuris
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES